Vibiosphen at GAMRIC 2026: Advancing Preclinical Research Against Antimicrobial Resistance

Vibiosphen is pleased to announce its participation in GAMRIC 2026, bringing together scientists, clinicians, biotechnology companies, pharmaceutical developers and other stakeholders committed to addressing one of the most pressing challenges in infectious diseases: antimicrobial resistance (AMR).

Robin Dumas will represent Vibiosphen during the event, providing an opportunity to meet with teams developing new antimicrobial therapies and discuss how relevant preclinical strategies can help accelerate their development.